Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOGF


Primary Symbol: C.ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Post by waves1on Oct 13, 2021 3:31pm
98 Views
Post# 34002477

Replay of $ACOG CEO at LD Micro Event!

Replay of $ACOG CEO at LD Micro Event! If you were unable to watch Alpha Cognition ($ACOG $ACOG.v $ACOGF)'s CEO present at the LD Micro Main Event, there is still a replay available at: https://me21.mysequire.com/ on Track 3 at 3pm on the October 12th page!

Highlights:
  • Overview of the science behind Alzheimer's and what needs to be done for treatment
  • Specifics of Alpha-1062 drug, how it works and the opportunities it has
  • Overview of studies and trials that have been done 
  • Comparison between Alpha-1062 and its competitors (spoiler: $ACOG blows their competitors out of the water, being the potential best-in-class drug) 
  • Investor considerations and upcoming catalysts
I'd highly recommend checking their presentation out, it gives a great understanding of the company and industry as a whole, while providing information for investors.

https://me21.mysequire.com/
<< Previous
Bullboard Posts
Next >>